All In Biotech

NDA 018321 · Curium

Technescan Hdp

Technetium Tc-99m Oxidronate Kit · Injection

Last checked: Nov 20, 2026Latest source record: Nov 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1981

Feb 18, 1981

Approved uses

2

Original approval plus efficacy supplements

Registered trials

0

0 Phase 3, 0 recruiting

FAERS reports

136

68 serious, 3 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 5, 2025.

INDICATIONS AND USAGE Technescan HDP, after radiolabeling with sodium pertechnetate Tc 99m, is indicated for skeletal imaging to demonstrate areas of altered osteogenesis in adult and pediatric patients.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 28, 1989 Supplement 8 · Efficacy
  • Feb 18, 1981 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
  • TECHNESCAN HDP · TECHNETIUM TC-99M OXIDRONATE KIT N/A · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Technetium Tc-99m Oxidronate Kit" as an intervention, any sponsor and status, largest first.

All 0 trials

No registered drug trials name this ingredient.

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea16
  • bone scan abnormal14
  • injection site pain10
  • drug ineffective9
  • headache9
  • injection site swelling8
  • injection site erythema7
  • injection site extravasation7
  • dizziness6
  • product administration error6
  • product preparation issue6
  • radioisotope scan abnormal6

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20044
20052
20071
20101
20122
20133
20145
20151
20163
20172
201811
20197
202011
202166
20221
20233
20245
20255
20263

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Curium

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.